| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $355,556,374 ) (Continued on the next page) |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study - Year 2 | 000 | 18 | NIH | 12/7/2022 | $913,654 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study - Year 2 | 000 | 18 | NIH | 12/7/2022 | $562,721 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study - Year 2 | 000 | 18 | NIH | 12/7/2022 | $4,487,239 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study - Year 2 | 000 | 18 | NIH | 12/7/2022 | $670,687 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study - Year 2 | 003 | 18 | NIH | 6/6/2023 | $1,680,043 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study - Year 2 | 001 | 18 | NIH | 3/10/2023 | $913,654 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study - Year 2 | 001 | 18 | NIH | 3/10/2023 | $4,487,239 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068617 | CoVPN 5002: SARS-CoV-2 Prevalence Study - Year 2 | 001 | 18 | NIH | 3/10/2023 | $670,687 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 022 | 18 | NIH | 9/14/2023 | $0 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 022 | 18 | NIH | 9/14/2023 | $0 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 022 | 18 | NIH | 9/14/2023 | $0 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 022 | 18 | NIH | 9/14/2023 | $0 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 015 | 18 | NIH | 3/29/2023 | $14,838,351 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 015 | 18 | NIH | 3/29/2023 | $540,609 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 015 | 18 | NIH | 3/29/2023 | $250,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 017 | 18 | NIH | 4/7/2023 | $2,683,830 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 018 | 18 | NIH | 4/28/2023 | $305,278 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 021 | 18 | NIH | 5/1/2023 | $19,404,520 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 006 | 18 | NIH | 1/4/2023 | $14,838,352 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 006 | 18 | NIH | 1/4/2023 | $7,634,355 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 006 | 18 | NIH | 1/4/2023 | $250,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 006 | 18 | NIH | 1/4/2023 | $500,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | U01AI069197 | Hematopoietic Stem Cell And Cord Blood Transplantation | 000 | 20 | NIH | 4/5/2023 | $200,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA114536 | Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | 001 | 18 | NIH | 1/12/2023 | $0 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01GM105785 | Statistical Methods for RNA-seq Data Analysis | 004 | 10 | NIH | 8/9/2023 | $437,166 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 001 | 18 | NIH | 11/17/2022 | $607,963 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068635 | HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals | 009 | 18 | NIH | 5/2/2023 | $12,647,369 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA189532 | Statistical Methods for Analysis of Tumor Heterogeneity in Genetic Epidemiology | 000 | 10 | NIH | 8/7/2023 | $407,644 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA175008 | Understanding and predicting relapse in acute myeloid leukemia | 000 | 11 | NIH | 5/5/2023 | $409,640 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL128239 | Genetic and molecular basis for SRSF2 mutations in myelodysplasia | 000 | 10 | NIH | 8/15/2023 | $791,584 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | D43TW009759 | Building independent research leaders in HIV-associated malignancies in Uganda | 000 | 10 | NIH | 4/4/2023 | $100,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | D43TW009759 | Building independent research leaders in HIV-associated malignancies in Uganda | 000 | 10 | NIH | 4/4/2023 | $198,787 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AR066248 | SMCHD1 Pathways as Candidate Targets for FSHD | 000 | 10 | NIH | 6/21/2023 | $430,192 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 006 | 18 | NIH | 6/1/2023 | $241,106 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 006 | 18 | NIH | 6/1/2023 | $159,108 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals | 010 | 18 | NIH | 6/20/2023 | $2,268,154 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older LC 3 | 024 | 18 | NIH | 7/3/2023 | $5,000,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U10CA180819 | SWOG Statistics and Data Management Center | 002 | 10 | NIH | 8/24/2023 | $228,051 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U10CA180819 | SWOG Statistics and Data Management Center | 001 | 10 | NIH | 6/21/2023 | $1,606,325 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 006 | 18 | NIH | 6/1/2023 | $607,963 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068635 | HVTN 405 HPTN 1901, Characterizing SARS-COV-2-Specific Immunity in Convalescent Individuals | 008 | 18 | NIH | 3/1/2023 | $14,833,900 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | UM1AI068618 | CoVPN 3003 A Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older LC 3 | 014 | 18 | NIH | 3/29/2023 | $1,010,139 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R01CA218285 | Immuno and Epigenetics of Hematopoietic Cell Transplantation | 002 | 7 | NIH | 5/17/2023 | $623,084 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI123323 | Inflammation-driven T Cell Responses and their Dichotomous Effect on Host Immunity | 002 | 8 | NIH | 7/27/2023 | $528,000 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | KING | USA | R35GM118120 | Molecular analysis of genetic recombination and DNA break repair | 002 | 9 | NIH | 4/24/2023 | $971,082 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM119774 | Real-time tracking of virus evolution for vaccine strain selection and epidemiological investigation | 002 | 9 | NIH | 6/7/2023 | $418,074 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R50CA211499 | A proteomics research specialist in developing targeted mass spectrometry methods for quantifying proteins important in cancer | 001 | 7 | NIH | 9/13/2023 | $28,082 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R50CA211499 | A proteomics research specialist in developing targeted mass spectrometry methods for quantifying proteins important in cancer | 000 | 7 | NIH | 8/30/2023 | $282,679 |
| | 2023 | 2023 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL130483 | Statistical methods for analyzing objectively measured physical activity. | 001 | 8 | NIH | 6/20/2023 | $447,927 |
|
